Insider Deck research · News

NTRA stock news · Natera, Inc.

Latest Natera, Inc. (NTRA) stock news, headlines, and research context on Insider Deck. Market cap $39.3B.

News desk

Natera, Inc. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

8 on the wireUpdated within the hour

Business Wire·Wed, Aug 5, 10:00 AM

Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

AUSTIN, Texas, August 05, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx).

Insider Deck desk note

Last$274.62
Day-0.21%
SymbolNTRA

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on Business Wire

Frequently asked questions

What is the latest news on NTRA?

The NTRA news desk aggregates recent headlines with research context for Natera, Inc..

Where can I research NTRA on Insider Deck?

Natera, Inc. (NTRA) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.